Background
In order to address global challenges, significant amounts of funding have been made available in high-income countries (HICs) in the last five years to conduct research with and in low- and middle-income countries (LMICs). Much of this funding has been used to support research in global health, including global mental health [1]. There is no overall accepted consensus on what exactly global mental health research should entail. One approach is that research should aim to test and implement evidence-based interventions in LMICs, most of which have exclusively been studied in HICs [2]. Such an approach has limitations: a) using current evidence-based interventions in a different context might be inappropriate and ineffective, particularly as most interventions in mental health care have only small to medium effect sizes; b) many interventions, such as the majority of formal psychological treatments, require significant funding and qualified professional staff, none of which is usually available in LMICs; and c) in various LMICs there are likely to be resources in individuals, families and communities, that may not exist to the same extent in HICs but can be utilised to help people alleviate or overcome the distress of mental disorders.
We therefore applied to the National Institute of Health Research (NIHR) in the United Kingdom (UK) to pursue a different approach. We were awarded funding for a NIHR Global Health Research Group on Developing Psycho-Social Intervention for Mental Health Care at Bart’s and the London School of Medicine and Dentistry (hereby referred to as The Group). The Group aims to establish partnerships of experts in HICs and LMICs, work in collaboration with local stakeholders to develop resource-oriented interventions for people with severe mental illness, and to conduct studies to test these interventions [3]. The interventions are intended to be low-cost and mainly use existing resources and social structures in LMICs. Therefore, if found to be effective, the interventions should facilitate sustainable implementation of effective community care for large numbers of people with severe mental illness (SMI). The three existing resources that we will utilise are a) contacts and meetings between patients and clinicians in the community as they occur in the given context; b) families and friends of patients; and c) volunteers in the community who are willing to spend time with and support patients with SMI. The research designs were all adapted and agreed with local stakeholders to ensure they fit with the local context, priorities and mental health needs. Through the work of the Group, we also intend to increase the expertise in research on psychosocial interventions in the partner countries and more generally to advance the conceptual understanding of what global mental health research may mean and achieve.
Anzeige
The Group consists of partners in Sarajevo (Bosnia-Herzegovina), Bogotá (Colombia), Kampala (Uganda) and London (UK). Bosnia-Herzegovina, Colombia and Uganda are all LMICs, all have aims to expand community care for people with SMI and all share a recent history of armed conflicts. Yet, they are on three different continents and have different traditions and cultures. This may facilitate the learning from commonalities and differences in experiences.
Methods
Interventions and study designs
The research conducted by the Group will test three aforementioned interventions - making patient-clinician meetings therapeutically effective through DIALOG+, family involvement in multi-family group meetings, and support for patients in befriending schemes with volunteers. Each intervention is tested in each country, i.e. there are nine studies in total. The study designs include non-controlled trials, non-randomised controlled trials and smaller and larger randomised controlled trials (RCTs). The main characteristics of the nine studies are summarised in Table 1, indicating core consistencies and differences in study designs across the three LMICs.
Table 1
Main characteristics of the nine studies that will be conducted in Bosnia-Herzegovina, Colombia and Uganda
Bosnia-Herzegovina | Colombia | Uganda | |
|---|---|---|---|
DIALOG+ | Cluster RCT, 72 patients with depression and anxiety, 14 clinicians, Control group = TAU | Cluster RCT, 168 patients with SMI, 14 clinicians, Control group = TAU | Cluster RCT, 168 patients with MNS, 14 clinicians, Active control group |
Family Involvement | RCT, 72 patients with SMI, 36–72 family members/friends, 6–12 clinicians, Control group = TAU | Non-controlled trial, 30 patients with SMI, 30–60 family members/friends, 6–12 clinicians, No control group | Controlled trial, 30 patients with SMI, 30–60 family members/friends, 6–12 clinicians, Control site |
Volunteer Support | RCT, 72 patients with SMI, 36 Volunteers, Control group = TAU | Non-controlled trial, 30 patients with SMI, 20 volunteers, No control group | Controlled trial, 30 patients with SMI, 10 volunteers, Control Site |
For each intervention (described below) there is some evidence for effectiveness from HICs, although that evidence is not always conclusive and does not necessarily apply to the precise form of the intervention as used in this research. Yet, all interventions can refer to theories for why they might be beneficial to patients and have been found by local stakeholders in each country to be relevant for the given context.
DIALOG+
DIALOG+ has been developed to turn routine meetings between a patient and mental health professional into a therapeutically effective intervention. It is based on quality of life research, concepts of patient-centred communication, developments in information technology, and components of solution-focused therapy. Supported by an App using a tablet computer, it delivers assessment, planning, intervention and evaluation in one procedure.
In the meeting with the mental health professional, patients rate their satisfaction with eight quality of life domains, and three treatment domains. The ratings are summarised on-screen, allowing for comparisons with ratings from any previous meeting. Patients can then decide which life and/or treatment domains they would like to discuss in the current meeting. Each selected life domain or treatment domain is addressed in a four-step solution-focused approach. The four steps are: 1) understanding (Why is the patient dissatisfied? What is nevertheless working well?); 2) looking forward (What is the best case scenario? What is the smallest step forward?); 3) exploring options (What can the patient, the mental health professional and others do?); and finally 4) agreeing on actions (What should be done between now and the next meeting?). The agreed actions are briefly documented and revisited at the beginning of the next meeting.
In an RCT in London, DIALOG+ was compared with an active control condition and was shown to lead to better quality of life, lower symptom levels, more favourable objective social situation and reduced health care costs for patients with schizophrenia [4‐6].
DIALOG+ will be tested in three cluster randomised controlled trials, in which mental health professionals and their patients, i.e. clusters, are randomly allocated either to the experimental or the control group. This design will prevent potential contamination effects between the groups and ensure that no professional who is trained in DIALOG+ administers it to a patient in the control group. DIALOG+ will be delivered by mental health professionals, once per month over a period of 6 months, as part of usual routine clinical meetings.
In each country, DIALOG+ will be administered to outpatients with SMI, diagnosed using International Classification of Diseases, Tenth Revision (ICD-10) criteria [7] by mental health professionals but with slight variations in the diagnosis and patient numbers based on the priorities expressed by national stakeholders and reflecting differences in national health and social care systems.
In Uganda, 168 patients with SMI defined as having been diagnosed with psychosis, bipolar, and/or mood affective disorders, (ICD-10 F20–29, F30-F39), epilepsy and/or comorbid substance abuse and 14 mental health professionals including nurses, social workers, psychiatric clinical officers, psychologists and psychiatrists will be part of the trial. The RCT in Uganda will comprise of an active control arm. Patients in the control group will also receive an intervention on a tablet, where they will be asked to complete the DIALOG scale which includes only satisfaction ratings, with minimal input from clinicians. This will be done at the end of their routine sessions so that the ratings will not influence the communication during the meeting.
In Colombia, 168 patients with SMI defined as having been diagnosed with psychosis, bipolar, and/or mood affective disorders (ICD-10 F20–29, F31, F32) will be included and all 14 mental health professionals will be qualified psychiatrists or psychiatric residents.
In Bosnia, a RCT will be conducted with 72 patients with severe depression and anxiety (ICD-10 F30-F39, F40-F49, excluding bipolar disorder) and 14 mental health professionals who will be qualified psychiatrists, psychologists or psychiatric residents.
Family involvement
Involving family members or friends in patient’s care can help to improve family communication, overall care and outcomes. The intervention will draw from the tradition of trialogue and psychosis-seminars, where mutual learning occurs through the sharing of experiences, support and psychoeducation on pre-agreed topics [8, 9]. In multi-family group meetings, approximately five to six patients with one or two family members or friends each and one or two mental health professionals will meet and discuss subjects that are defined and selected by the participants. The family intervention sessions will be held once per month, over six months at local community or health centres, or easily accessible locations.
The meetings will normally be chaired by a mental health professional, but the group can also decide to have a patient or family member to chair the meeting or to rotate that role. The meetings follow some basic rules ensuring mutual respect, but are otherwise flexible to accommodate the priorities and wishes of the participants. For the proposed research studies, mental health professionals can be psychiatric community officers, occupational therapists, social workers, nurses, psychiatrists or psychologists.
In Bosnia-Herzegovina, family involvement will be tested in an exploratory RCT where 72 patients with schizophrenia and non-affective psychosis (ICD-10 F20–29) will be recruited and randomly allocated either to family involvement or the control group without family involvement, whilst both groups otherwise continue to receive treatment as usual. In Colombia and Uganda the intervention will be tested in open trials with 30 patients (ICD-10 F20–29, F30-F39) each. In Colombia the trial will be non-controlled. The study design in Uganda includes an additional control site against which patient outcomes will be compared. This control site in Uganda will recruit 30 patients who will continue to receive treatment as usual and will be followed up at the same time points as the intervention participants.
Across all the family involvement studies, the same mental health professional will participate in a maximum of two multi-family groups. This is to avoid any overall effect being dominated by the influence of only one or two individual professionals.
Volunteer support
Unpaid volunteers (rather than professionals) are linked with one or more patients to provide psychological, social and practical support, a concept that is often referred to as befriending. The support may be focused on talking, joint activities, expanding social networks or practical support (such as vocational rehabilitation). Volunteer support in befriending programmes is supposed to benefit the patient as well as the volunteer and to strengthen the cohesion and acceptance of patients with mental disorders in the community. Whilst the effects on volunteers themselves and on wider communities have not been systematically studied, there is some evidence suggesting benefits for patients [10‐12].
For the proposed research studies, volunteers will be drawn from different backgrounds including university students, the general public and religious communities. All volunteers will be provided with a short training before beginning the intervention and are expected to meet with their matched patients every two weeks for six months.
The study design used to test the volunteer support intervention varies across countries. In Bosnia-Herzegovina, a RCT will be conducted with 72 patients (ICD F20–29) who will be allocated to have one-to-one meetings with a volunteer or to a control group without any volunteer input. Both groups will continue to receive treatment as usual.
Similar to the study on family involvement, the study design for volunteer support in Colombia and Uganda will be open trials with 30 patients. In Colombia the trial will be non-controlled whereas in Uganda patient outcomes will be compared to the aforementioned control group. For both countries, two volunteers will meet small groups of three to six patients. The proposed activities vary: in Uganda the intervention will focus on one or two of the following tasks i) increasing social activity/interactions; ii) engaging in productive, e.g. income-generating, activities; iii) providing practical support for accessing and utilising available professional services and care; and iv) referrals to such services if and when appropriate. It will be up to each group of patients and volunteers to decide which of these tasks to focus on. In Bosnia-Herzegovina and Colombia, the intervention is focused more towards social activities/interactions e.g. visiting parks, museums, and going to cafes. As music and art plays a strong role in the Colombian culture, the social activities may involve producing art and music.
Patients and timescale
Patients are eligible if they are 18–65 years of age, have been diagnosed with the type of SMI required in each study, are currently outpatients, and have capacity to provide informed consent. Exclusion criteria are any cognitive impairment that would compromise valid research assessments.
The time period for all interventions will be six months. After the six months intervention period, patients, volunteers, family members and professionals are free to continue with the given intervention, in the original or a different form and in any frequency that the participants may wish to use. After the six months test period the interventions will receive minimal or no support from the research team.
Data collection for all participants in all studies will take place at baseline, at the end of the intervention period (six months) and at follow up (twelve months). All assessments for data collection will be conducted by trained researchers with no involvement in the usual treatment of the patients or the tested interventions. Adherence to the intended intervention will be assessed in all trials.
In the RCTs, clinicians and participants cannot be blinded towards the allocation of the patients to the experimental or control group. However, researchers who conduct the outcome assessments will be blinded to the allocation of patients. Moreover, all baseline assessments will occur prior to randomisation. Randomisation will be conducted by an independent researcher who will use sequential computer generated random numbers to determine allocation. The allocation information will be provided to the unblinded research coordinator at each site. The intervention period begins from the date of randomisation and for all other trials, i.e. non-RCTs, the intervention period begins with the first multi-family meeting or the allocation of patients and volunteers. A summary of the schedule for patients in all DIALOG+ RCTs and Family Involvement and Volunteer Support RCTs in Bosnia-Herzegovina can be found in Tables 2, 3 and 4 respectively.
Table 2
Schedule of enrolment, interventions, and assessments for patients in the DIALOG+ study (all sites)
Timepoint | Study period | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Enrolment | Allocation | Post-allocation | Close out | ||||||||
-t
1
| Month 0 |
t
1 Month 0
|
t
2 Month 1
|
t
3 Month 2
|
t
4 Month 3
|
t
5 Month 4
|
t
6 Month 5
|
t
7 Month 6
|
Flexible period Month 7–12
|
Month 12
| |
ENROLMENT: | |||||||||||
Eligibility screen | X | ||||||||||
Informed consent | X | ||||||||||
MANSA Screening
| X | ||||||||||
Allocation | X | ||||||||||
INTERVENTIONS: | |||||||||||
DIALOG+
| X | X | X | X | X | X | X | X | |||
DIALOG Scale – only in Uganda
| X | X | X | X | X | X | X | X | |||
Treatment as Usual – Bosnia and Herzegovina and Colombia
| X | X | X | X | X | X | X | X | |||
ASSESSMENTS: | |||||||||||
Socio-demographic Questionnaire
| X | ||||||||||
MANSA, BPRS, SIX, CSRI, Additional measures (vary by site)
| X | X | X | ||||||||
Adherence Measures
| X | X | X | X | X | X | X | X | |||
Table 3
Schedule of enrolment, interventions, and assessments for patients in the Family Involvement Intervention in Bosnia-Herzegovina
Timepoint | Study period | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Enrolment | Allocation | Post-allocation | Close out | ||||||||
-t
1
| Month 0 |
t
1 Month 0
|
t
2 Month 1
|
t
3 Month 2
|
t
4 Month 3
|
t
5 Month 4
|
t
6 Month 5
|
t
7 Month 6
|
Flexible period Month 7–12
|
Month 12
| |
ENROLMENT: | |||||||||||
Eligibility screen | X | ||||||||||
Informed consent | X | ||||||||||
MANSA Screening
| X | ||||||||||
Allocation | X | ||||||||||
INTERVENTIONS: | |||||||||||
Family Involvement Sessions
| X | X | X | X | X | X | X | X | |||
ASSESSMENTS: | |||||||||||
Socio-demographic Questionnaire
| X | ||||||||||
MANSA, BPRS, SIX, CSRI, ITAQ
| X | X | X | ||||||||
Adherence Measures
| X | X | X | X | X | X | X | X | |||
Table 4
Schedule of enrolment, interventions, and assessments for patients of the Volunteer Support in Bosnia-Herzegovina
Timepoint | Study period | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Enrolment | Allocation | Post-allocation (weeks) | Close out | ||||||||||||||
-t
1
| Month 0 |
t
1 0
|
t
2 2
|
t
3 4
|
t
4 6
|
t
5 8
|
t
6 10
|
t
7 12
|
t
8 14
|
t
9 16
|
t
10 18
|
t
11 20
|
t
12 22
|
t
13 24
|
Flexible period Month 7–12
|
Month 12
| |
ENROLMENT: | |||||||||||||||||
Eligibility screen | X | ||||||||||||||||
Informed consent | X | ||||||||||||||||
MANSA Screening
| X | ||||||||||||||||
Allocation | X | ||||||||||||||||
INTERVENTIONS: | |||||||||||||||||
Volunteer Support Sessions
| X | X | X | X | X | X | X | X | X | X | X | X | X | X | |||
ASSESSMENTS: | |||||||||||||||||
Socio-demographic Questionnaire
| X | ||||||||||||||||
MANSA, BPRS, SIX, CSRI
| X | X | X | ||||||||||||||
Adherence Measures
| X | X | X | X | X | X | X | X | X | X | X | X | X | X | |||
Measures
Data will be collected using a standardised Case Report Form (CRF) and each partner site will be collecting the same core outcome measures for all recruited patients. All CRFs have been translated into the relevant local language. Country specific CRFs are available upon request.
Anzeige
At baseline, we will obtain socio-demographic and clinical characteristics including gender, age, ethnicity, highest level of education, employment, mental and physical diagnoses. Further assessed socio-demographic and clinical data vary slightly across countries to capture the most locally relevant information.
At baseline, six and twelve months we will assess:
Subjective quality of life using the Manchester Short Assessment of Quality of Life (MANSA) [13]. The MANSA has been widely used in mental health research and contains satisfaction items with 12 life domains which are rated by the patient between 1 (most negative score) and 7 (most positive score). The mean score of those 12 items is used to reflect subjective quality of life.
In all trials, the MANSA will be used as the primary outcome at six months and in all controlled trials, the MANSA is also used as a screening tool. To avoid including patients with high levels of subjective quality of life at baseline that cannot substantially improve during the study anymore, only patients with a mean score of < 5 are eligible to take part in the study.
Mental Health Symptoms will be observer rated on the 24-item Brief Psychiatric Rating Scale (BPRS) [14]. Each symptom is assessed and rated between 1 (not present) and 7 (extremely severe) using a scoring guide. The BPRS guide has been translated into the local languages, and all researchers will be trained in BPRS assessments and interrater-reliability will be established prior to baseline data collection.
Objective Social Outcomes will be assessed using the SIX which ranges from 0 (poorest social situation) to 6 (best social situation) and captures whether patients are in employment, have independent accommodation, are living with others and have contacts with friends [15].
Use of mental health services will be documented on a simplified version of the Client Service Receipt Inventory (CSRI) [16]. Information on medication use, contact with mental health professionals and any instances of hospitalisation in the last three months will be recorded.
Whilst the above measures are consistently used across countries and studies, further measures are used in only some studies to ensure data collection matches local health priorities. These are listed in Table 5.
Table 5
Additional outcome measures to be collected within each country
Additional Outcome Measures | Bosnia- Herzegovina | Uganda | Colombia | |
|---|---|---|---|---|
Patients | Internalised Stigma of Mental Illness Inventory [17] | Volunteer Support | All studies | Volunteer Support |
Scale to Assess Therapeutic Relationships in Community Mental Health Care (STAR-P) [18] | DIALOG+ | |||
Client Satisfaction Questionnaire-8 (at 6 and 12 months) [19] | All studies | |||
Self-Esteem Rating Scale [20] | All studies | |||
Depression and Anxiety Stress Scale [21] | DIALOG+ | |||
Insight and Treatment Attitudes Questionnaire (ITAQ) [22] | Family Involvement | |||
Medication Adherence Rating Scale [23] | All studies | |||
Clinicians | Scale to Assess Therapeutic Relationships in Community Mental Health Care (STAR-C) [18] | DIALOG+ | ||
Family Members/Friends | Burden Scale for Family Caregivers [24] | Family Involvement | ||
Community Attitudes Towards Mental Illness Scale [25] | Family Involvement | |||
Zarit Burden Interview [26] | Family Involvement | |||
Volunteers | Community Attitudes Towards Mental Illness Scale [25] | Volunteer Support | Volunteer Support | |
Social Distance Questionnaire [27] | Volunteer Support | |||
Self-esteem Rating Scale [20] | Volunteer Support |
Anzeige
Sample size calculations
Formal sample size calculations were conducted for the DIALOG+ RCTs in Uganda and Colombia in order to detect a medium effect size of 0.5, setting power at 80% for 5% significance. The total number of patients required is 64 per group (n = 128). After accounting for clustering of patients treated by the same clinician, based on an Intra-Cluster-Coefficient of 0.01 as observed within the DIALOG+ trial in the UK [28], a conservative design effect of 1.04, and allowing for a drop-out rate of 17%, a total of 168 patients will need to be recruited to give an analysable sample of 140 (70 per group).
Estimates for exploratory randomised controlled trials vary, but it has been suggested that a minimum of 30 participants per arm are required [29]. Therefore in Bosnia-Herzegovina, the sample size for all RCTs include 36 per arm, to allow for a 20% drop out rate which has been demonstrated in previous research with individuals with psychosis [30].
For all other controlled and non-controlled trials, we plan a sample size of 30 participants per arm or in total respectively. Central limit theory suggests 30 as a minimum sample size to enable meaningful parameter estimates [31, 32].
The plan to have larger studies on DIALOG+ than on family involvement and volunteer support reflects a particular interest of stakeholders in each country who felt that DIALOG+ may play an important role in the further development and establishment of community mental health care in the participating countries.
Anzeige
Experiences with the interventions
At the end of the six month intervention period, a subset of participants (patients, clinicians, family members/friends and volunteers) who were allocated to the interventions will complete semi-structured, in-depth interviews about their experiences of receiving the interventions, with unblinded researchers. Purposive sampling will be employed to capture patients with varying levels of engagement with their clinician/volunteer/family group and with different outcomes. The interviews will be audio recorded, transcribed and analysed using the thematic analysis framework proposed by Braun and Clarke [33].
Commonalities and differences
Whilst the type of interventions, target groups of patients with SMI, timelines and core outcome criteria are consistent across all studies in all countries, there are differences in the precise diagnostic inclusion criteria, the study designs and some outcome criteria. The most important commonalities and differences of the studies in the three countries are summarised in Table 6
Table 6
Similarities and differences across the nine research studies in three LMICs
Consistent | Variable |
|---|---|
Intervention period for 6 months | |
Principles of interventions | Details of interventions |
Patients with severe mental illness | Precise diagnostic groups |
Outcome assessments | Trial designs: |
- Baseline - 6 months (post-intervention) - 12 months | - Non-controlled, non-randomised controlled and RCTs - Sample sizes - Blinded and non-blinded |
Core outcome criteria: | Further outcome criteria includes: |
- Objective social situation (SIX) | - Caregiver burden |
- Subjective quality of life (MANSA) | - Stigma |
- Symptoms (BPRS) | - Medication adherence |
- Service use (CSRI adapted) | - Self esteem |
Settings
In Bosnia and Herzegovina, all research activities will take place at the Clinical Centre University of Sarajevo.
In Colombia, the DIALOG+ study will take place at various sites in Bogotá (San Ignacio hospital, Clínica la Inmaculada, Clínica Fray Bartolomé) and Hospital Departamental Psiquiátrico Universitario del Valle ESE, Cali. The Family involvement and Volunteer support studies will recruit patients mainly from the Association of Persons with Schizophrenia and their Families and the Bipolar Patients Association, but they will also accept referrals from the participating research sites in Bogotá.
In Uganda, the DIALOG+ study will take place in Kampala at Butabika Mental Health Hospital and its surrounding outreach clinics. Three mental health clinics (or centres) in different areas of the country were randomised to one of three arms: Family involvement study (Masaka), Volunteer support study (Jinja) and Control (Mitiyana).
Data management and analysis
All data will be collected on paper-based CRFs and pseudonymised data will be entered onto a secure shared electronic database, REDCap, accessible to all partners. The electronic database will contain validations to ensure accurate data entry. Local coordinators and the UK team will provide regular monitoring to ensure accurate data collection and entry. All patient-identifiable data will be pseudonymised and password-protected at the local research site.
The studies will first be analysed separately, where the mean MANSA score will be compared before and after the intervention as well as between intervention and control arms (for all controlled studies). We will also combine the datasets. The consistencies in the interventions and study designs will make it possible to compare findings and experiences and learn from commonalities and differences. Detailed statistical analysis plans will be completed and signed off by all relevant partners prior to any data analysis or unblinding of the data. Once signed off, the plans will be available on request. The director of the Group will have access to the final dataset.
Monitoring
An overall Advisory Group has been established for the whole research programme of the NIHR Global Health Research Group. It comprises members who are independent of the organisations involved in the research. Members have expertise in mental health care in the partner countries, global mental health, research methodology and implementation of study designs, including RCTs, in community settings. Their role is equivalent to a Steering Group and covers the research programme as a whole, as well as individual studies. A formal Data Monitoring Committee was not established as this function will be covered by the Advisory Group, who will provide input on data monitoring, if and as required.
Dissemination
The findings will be disseminated to national stakeholders, including policy makers, mental health workers and the general public. Dissemination events will be held in each country. The findings will be shared with the scientific community in national and international conferences and in open access publications. The general availability of the data sets varies in line with the conditions set by local ethics committees and research governance rules. Yet, all data sets will be made available upon request subject to data sharing agreements.
In addition to the findings of the studies themselves, we will also publish reflective articles about the experiences with refining interventions and study designs in partnership with national stakeholders and conducting studies with similarities and differences across three LMICs.
Discussion
The approach of the research group to establish a partnership across countries on three continents and explore resource-oriented interventions for community mental health care for people with SMI has led to nine separate study protocols. The content and design of the studies were developed in workshops, consultations and discussion groups at all sites. In each LMIC, each considered intervention was discussed in depth and in partnership with local stakeholders considering the local context, healthcare priorities, practicalities and logistics of conducting the research studies, as well as potential study sites, participants and study designs. Workshop attendees included different groups of mental health professionals, researchers, government officials and representatives, volunteers, peer support workers, representatives from patient and family organisations, non-government organisations and student organisations. These events and regular on-going communication among all partners led to protocols for the three types of resource-oriented interventions and for studies testing them.
The study designs which are non-controlled or non-randomised may provide limited conclusions on effectiveness whilst the exploratory RCTs have relatively small sample sizes providing limited statistical power for detecting effects. However, we believe they will provide valuable insight into the feasibility and acceptability of such interventions in the relevant contexts.
The protocols show substantial consistencies across the three LMICs but at the same time, there are a number of variations reflecting different contexts of national health and social care systems and the specific priorities and wishes of national stakeholders. This approach is distinct from a conventional multi-centre study and required excellent collaboration and communication both across and within the partner countries. Each of the nine studies will primarily be analysed separately. Yet, the consistencies in the interventions and the study designs will make it possible to compare findings and learn from commonalities and differences in the findings and experiences. To our knowledge, this is an unusual and somewhat innovative approach in global mental health research. The results of the studies may show to what extent such designs across several countries do or do not reveal additional insights. The approach also ensured a relevance to the different national contexts so that the findings can potentially impact on health policies and clinical practice in each country.
Through these research studies and activities, the Group aims to encourage sharing and learning across contexts thereby building sustainable research capacity and exploring and deepening the understanding of global mental health.
Anzeige
Acknowledgements
Not applicable.
Opinions of ethics committees
All studies have received positive ethical opinions from the relevant ethics committees both in the given LMIC and the UK.
For studies in Bosnia-Herzegovina:
1.
The clinical Centre University of Sarajevo School of medicine research ethics committee (Eticki Komitet), approval received on 18/09/2018
2.
Queen Mary ethics of research committee: positive opinion received 30/10/ 2018, ref: QMERC2018/66
For studies in Colombia:
1.
IRB of Javeriana University, approval received on 19/09/2018, Ref: 2018/122.
2.
Ethics Committee of the Hospital Departamental Psiquiátrico Universitario del Valle, Cali, approval received on 08/10/2018.
3.
Ethics Committee of Clínica La Inmaculada, approval received on 16/07/2018.
4.
Ethics Committee of Clínica Fray Bartolomé: approval received on 14/11/18.
5.
Queen Mary Ethics of Research Committee: positive opinion received 30/10/2018, Ref: QMERC2018/59.
For studies in Uganda:
1.
Makerere University College of Health Sciences, School of Medicine Research Ethics Committee, approval received on 19/09/2018, Ref: 2018–096.
2.
Uganda National Council for Science and Technology, approval received on 01/11/2018, Ref: SS 4807.
3.
Queen Mary Ethics of Research Committee, positive opinion received 30/10/2018, Ref: QMERC2018/67.
The detailed study protocols and consent forms for each of the nine studies are available from the authors upon request.
Clinical trial registration
All RCTs were registered prospectively and non-randomised trials retrospectively within the ISRCTN Registry.
DIALOG+ in Uganda: ISRCTN25146122 (Date of Registration: 20/11/2018, prospective); DIALOG+ in Colombia: ISRCTN83333181 (Date of Registration: 20/11/2018, prospective); DIALOG+ in Bosnia-Herzegovina: ISRCTN13347129 (Date of Registration: 20/11/2018, prospective); Volunteer Support in Uganda: ISRCTN86689958 (Date of Registration: 04/03/2019, retrospective); Volunteer Support in Colombia: ISRCTN72241383 (Date of Registration: 04/03/2019, retrospective);Volunteer Support in Bosnia-Herzegovina: ISRCTN51290984 (Date of Registration: 20/11/2018, prospective); Family Involvement in Uganda: ISRCTN78948497(Date of Registration: 04/03/2019, retrospective); Family Involvement in Colombia: ISRCTN11440755 (Date of Registration: 04/03/2019, retrospective); Family Involvement in Bosnia-Herzegovina: ISRCTN13347355 (Date of Registration: 20/11/2018, prospective).
Funding
This research was peer-reviewed and commissioned by the National Institute for Health Research (NIHR) - [NIHR Global Health Group on Developing Psycho-Social Interventions] Grant number 16/137/97, using Official Development Assistance (ODA) funding. The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.
Availability of data and materials
The datasets used and/or analysed during the current study will be available from the corresponding author on reasonable request.
Ethics approval and consent to participate
All participants taking part in the nine studies are required to provide written informed consent before being able to take part in the studies. No risk to participants is expected, and all participants can terminate their participation at any time without any negative consequences – other than not receiving the potential benefits of the intervention. However, any adverse events occurring during the study period will be recorded.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests related to the research studies outlined in this protocol paper.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.